Shares of Abbott Laboratories (NYSE:ABT) have been given an average recommendation of “Buy” by the nineteen ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $85.82.
A number of brokerages recently issued reports on ABT. Raymond James raised their price target on Abbott Laboratories from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, July 18th. Jefferies Financial Group raised their price target on Abbott Laboratories from $80.00 to $98.00 and gave the stock a “buy” rating in a research note on Thursday, July 18th. Bank of America reissued a “buy” rating and set a $81.00 price target on shares of Abbott Laboratories in a research note on Thursday, June 13th. Wells Fargo & Co raised their price target on Abbott Laboratories from $89.00 to $91.00 and gave the stock an “outperform” rating in a research note on Thursday, June 13th. Finally, Cowen raised their price target on Abbott Laboratories from $86.00 to $95.00 and gave the stock an “outperform” rating in a research note on Thursday, July 18th.
In other Abbott Laboratories news, insider Daniel Gesua Sive Salvadori sold 10,600 shares of Abbott Laboratories stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $82.00, for a total transaction of $869,200.00. Following the completion of the sale, the insider now directly owns 99,479 shares of the company’s stock, valued at approximately $8,157,278. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Brian J. Blaser sold 450,062 shares of Abbott Laboratories stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $75.52, for a total value of $33,988,682.24. Following the sale, the insider now directly owns 295,745 shares of the company’s stock, valued at $22,334,662.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 815,831 shares of company stock valued at $65,150,090. 0.70% of the stock is currently owned by corporate insiders.
Shares of ABT stock traded down $1.02 on Thursday, reaching $86.08. 6,620,989 shares of the company’s stock were exchanged, compared to its average volume of 5,684,600. Abbott Laboratories has a 52 week low of $63.07 and a 52 week high of $88.76. The company has a quick ratio of 1.13, a current ratio of 1.58 and a debt-to-equity ratio of 0.61. The company has a market cap of $153.73 billion, a PE ratio of 29.89, a PEG ratio of 2.49 and a beta of 1.10. The business has a fifty day moving average of $85.25.
Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, July 17th. The healthcare product maker reported $0.82 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.80 by $0.02. Abbott Laboratories had a return on equity of 17.39% and a net margin of 9.36%. The firm had revenue of $7.98 billion during the quarter, compared to analyst estimates of $8 billion. During the same period last year, the company earned $0.73 EPS. Abbott Laboratories’s quarterly revenue was up 2.7% compared to the same quarter last year. Equities analysts predict that Abbott Laboratories will post 3.24 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Shareholders of record on Monday, July 15th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 1.49%. The ex-dividend date of this dividend is Friday, July 12th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 44.44%.
Abbott Laboratories Company Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
Further Reading: How to Track your Portfolio in Google Finance
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.